

Baseline immunosuppression changed							
Therapy added							
Biologic	1 (1%)	1 (3%)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4%)
Conventional DMARD	4 (5%)	1 (3%)	1 (14%)	0 (0)	0 (0)	0 (0)	2 (8%)
Immunomodulatory	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Glucocorticoid	1 (1%)	2 (7%)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4%)
Therapy increased							
Biologic	3 (4%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Non-biologic DMARD	1 (1%)	1 (3%)	0 (0)	0 (0)	0 (0)	0 (0)	3 (12%)
Immunomodulatory	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Glucocorticoid	1 (1%)	6 (20%)	0 (0)	1 (3%)	1 (14%)	0 (0)	1 (4%)
Flare symptoms							
Worsening symptom	69 (95%)	28 (93%)	7 (100%)	4 (67%)	6 (86%)	1 (50%)	26 (100%)
Worsening joint pain	59 (81%)	20 (67%)	5 (71%)	2 (33%)	1 (14%)	1 (50%)	21 (81%)
Worsening joint stiffness	45 (62%)	14 (47%)	5 (71%)	1 (17%)	1 (14%)	1 (50%)	12 (46%)
Worsening fatigue	31 (42%)	18 (60%)	4 (57%)	3 (50%)	4 (57%)	1 (50%)	14 (54%)
Worsening joint swelling	42 (58%)	12 (40%)	3 (43%)	0 (0)	1 (14%)	0 (0)	12 (46%)
Worsening muscle pain	24 (33%)	15 (50%)	6 (86%)	3 (50%)	1 (14%)	0 (0)	12 (46%)
Worsening keratoconjunctivitis sicca	10 (14%)	11 (37%)	5 (71%)	2 (33%)	0 (0)	0 (0)	9 (35%)
Worsening muscle weakness	11 (15%)	5 (17%)	2 (29%)	3 (50%)	0 (0)	1 (50%)	10 (38%)
Worsening GI symptoms	10 (14%)	5 (17%)	2 (29%)	2 (33%)	1 (14%)	0 (0)	9 (35%)
Worsening xerostomia	6 (8%)	7 (23%)	5 (71%)	1 (17%)	0 (0)	1 (50%)	8 (31%)
Worsening rash	6 (8%)	5 (17%)	1 (14%)	3 (50%)	1 (14%)	0 (0)	7 (27%)
Worsening Raynaud's syndrome	3 (4%)	7 (23%)	0 (0)	2 (33%)	0 (0)	1 (50%)	8 (31%)
Worsening shortness of breath	2 (3%)	3 (10%)	1 (14%)	2 (33%)	1 (14%)	0 (0)	9 (35%)
Worsening chest pain	2 (3%)	3 (10%)	0 (0)	1 (17%)	2 (29%)	0 (0)	5 (19%)
Worsening oral ulcer(s)	2 (3%)	5 (17%)	0 (0)	0 (0)	1 (14%)	0 (0)	3 (12%)
Worsening skin tightening	1 (1%)	3 (10%)	0 (0)	2 (33%)	1 (14%)	1 (50%)	0 (0)
Worsening nasal ulcer(s)	1 (1%)	3 (10%)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8%)
Worsening alopecia	1 (1%)	1 (3%)	2 (29%)	1 (17%)	0 (0)	0 (0)	1 (4%)
Worsening kidney function	0 (0)	1 (3%)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8%)
Worsening proteinuria	0 (0)	1 (3%)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4%)
New symptom	47 (64%)	23 (77%)	4 (57%)	6 (100%)	7 (100%)	2 (100%)	20 (77%)
New joint pain	22 (30%)	7 (23%)	2 (29%)	1 (17%)	2 (29%)	0 (0)	5 (19%)
New joint swelling	22 (30%)	4 (13%)	2 (29%)	1 (17%)	1 (14%)	1 (50%)	4 (15%)
New muscle pain	17 (23%)	8 (27%)	2 (29%)	0 (0)	1 (14%)	0 (0)	7 (27%)

New joint stiffness	19 (26%)	4 (13%)	1 (14%)	1 (17%)	1 (14%)	0 (0)	5 (19%)
New muscle weakness	11 (15%)	2 (7%)	1 (14%)	0 (0)	0 (0)	1 (50%)	3 (12%)
New oral ulcer(s)	6 (8%)	4 (13%)	1 (14%)	0 (0)	1 (14%)	1 (50%)	4 (15%)
New fever	7 (10%)	1 (3%)	0 (0)	1 (17%)	1 (14%)	0 (0)	3 (12%)
New urticaria	4 (5%)	0 (0)	0 (0)	0 (0)	1 (14%)	0 (0)	2 (8%)
New xerostomia	0 (0)	6 (20%)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4%)
New nasal ulcer(s)	0 (0)	4 (13%)	0 (0)	0 (0)	1 (14%)	0 (0)	3 (12%)
New other rash	3 (4%)	1 (3%)	0 (0)	3 (50%)	0 (0)	0 (0)	1 (4%)
New malar rash	2 (3%)	2 (7%)	0 (0)	0 (0)	0 (0)	0 (0)	4 (15%)
New Gottron's papules	0 (0)	3 (10%)	0 (0)	0 (0)	1 (14%)	0 (0)	3 (12%)
New skin tightening	3 (4%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (12%)
New keratoconjunctivitis sicca	2 (3%)	0 (0)	0 (0)	1 (17%)	0 (0)	1 (50%)	2 (8%)
New shortness of breath	4 (5%)	0 (0)	0 (0)	0 (0)	2 (29%)	0 (0)	1 (4%)
New chest pain	0 (0)	2 (7%)	0 (0)	0 (0)	1 (14%)	1 (50%)	1 (4%)
New V-sign rash	1 (1%)	1 (3%)	0 (0)	0 (0)	0 (0)	0 (0)	2 (8%)
New heliotrope rash	1 (1%)	0 (0)	0 (0)	1 (17%)	0 (0)	1 (50%)	2 (8%)
New discoid rash	0 (0)	2 (7%)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4%)
New proteinuria	1 (1%)	2 (7%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
New Raynaud's syndrome	0 (0)	1 (3%)	1 (14%)	0 (0)	0 (0)	0 (0)	1 (4%)
New shawl rash	1 (1%)	1 (3%)	0 (0)	1 (17%)	0 (0)	0 (0)	0 (0)
New alopecia	1 (1%)	1 (3%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

